CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 223 enrolled
Drug / intervention
Methoxy polyethylene glycol epoetin betadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02596945
NCT02596945N/ACompleted
CompareCT.gov

Non-Interventional Observation Trial to Investigate the Efficacy, Safety and Usability of Mircera in PD Patients in Daily Use

Hoffmann-La Roche·observational·Posted Nov 4, 2015·Updated Jul 2, 2017

In Brief

An observational study evaluating Methoxy polyethylene glycol epoetin beta for Renal Impairment and Renal Anemia of Chronic Kidney Disease. Completed, enrolled 223 participants across 1 site.

Detailed Summary

This non-interventional, observational study investigates the efficacy, safety and usability of methoxy polyethylene glycol epoetin beta in participants on peritoneal dialysis. Participants who were prescribed methoxy polyethylene glycol epoetin beta by their doctor and who meet the selection criteria were to be enrolled and documented in this study for a period of 9 months of treatment with methoxy polyethylene glycol epoetin beta with respect to efficacy, safety and usability.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Impairment, Renal Anemia of Chronic Kidney Disease
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 4, 2015
Enrollment StartJul 31, 2009
Primary CompletionFeb 28, 2011
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.7 years ago

Interventions

Methoxy polyethylene glycol epoetin betadrug

Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).